Paper Details

  1. Home
  2. Paper Details

Oral disease-modifying therapies for relapsing-remitting multiple sclerosis.

Author: ThomasRachel Hutchins, WakefieldRichard A

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This article reviews the efficacy and safety of the three oral agents approved by the Food and Drug Administration for the treatment of relapsing-remitting multiple sclerosis. These agents, fingolimod, teriflunomide, and dimethyl fumarate, were shown to be superior to placebo in reducing the annualized relapse rate and improving neuroradiological outcomes. Each agent had an acceptable safety profile, but the safety profiles differed.
Paper Details　
Original Abstract of the Article :
PURPOSE: The efficacy and safety of the three oral agents approved by the Food and Drug Administration for the treatment of relapsing-remitting multiple sclerosis (RRMS) are reviewed. SUMMARY: Limitations to parenteral disease-modifying therapies (DMTs) (interferon beta-1a, interferon beta-1b, and ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.2146/ajhp140023

データ提供：米国国立医学図書館（NLM）

Oral Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis (RRMS)

The world of multiple sclerosis (MS) is a vast and often challenging desert for both patients and researchers. This study explores the efficacy and safety of three oral disease-modifying therapies (DMTs) for relapsing-remitting MS (RRMS), offering a glimpse into the potential for more convenient and effective treatment options.

Oral DMTs: Navigating the Desert of MS Treatment

The study highlights the significant progress made in treating RRMS with the advent of oral DMTs. These agents offer advantages over traditional parenteral treatments, providing patients with more convenient and flexible options. The authors discuss the clinical trial findings, comparing the efficacy of fingolimod, teriflunomide, and dimethyl fumarate to placebo.

Navigating the Side-Effect Oasis

The study also emphasizes the need for ongoing safety monitoring of oral DMTs. While these agents have demonstrated acceptable safety profiles in clinical trials, long-term studies are crucial to ensure their continued efficacy and minimize the risk of potential side effects. It's like navigating a desert landscape – careful observation and vigilance are essential for a safe journey.

Dr.Camel's Conclusion

This research showcases the dynamic landscape of MS treatment, with promising advancements on the horizon. Finding the right DMT for each patient is like selecting the best path through the desert – a journey that requires careful consideration of both benefits and risks.

Date :
  1. Date Completed 2015-08-11
  2. Date Revised 2021-12-03
Further Info :

Pubmed ID

25511835

DOI: Digital Object Identifier

10.2146/ajhp140023

Related Literature

Article Analysis
・Effects of interferon beta-1b injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.